Table 3.
Correlations Between Biological Markers and Clinical Features at Follow-Up
| Coefficient of correlation | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Prolactin | Oxytocin | Homocysteine | |||||||
| Total | Women | Men | Total | Women | Men | Total | Women | Men | |
| PANSS Positive | 0.178 | −0.287 | 0.365* | −0.167 | −0.456 | −0.072 | −0.155 | 0.317 | −0.35* |
| PANSS Negative | −0.447* | −0.433 | −0.492** | −0.052 | 0.151 | −0.199 | −0.034 | 0.063 | −0.036 |
| PANSS General | −0.062 | −0.470 | 0.072 | −0.093 | 0.002 | −0.206 | 0.027 | 0.214 | −0.026 |
| PANSS Total | −0.240 | −0.481 | −0.052 | 0.036 | −0.010 | −0.228 | −0.061 | 0.184 | −0.072 |
| GAF | −0.009 | 0.049 | −0.093 | −0.125 | −0.202 | 0.023 | 0.058 | −0.072 | 0.021 |
| DDD of CPZ eq. | 0.058 | −0.264 | 0.231 | −0.123 | −0.119 | −0.176 | 0.098 | −0.040 | 0.142 |
Abbreviations: DDD of CPZ eq., Defined daily dose of chlorpromazine equivalent; GAF, overall functioning score; PANSS, Positive and Negative Syndrome Scale. *Statistically significant correlation (Spearman or Pearson correlations: *P < .05, **P < .01).